PTGX
Price:
$41
Market Cap:
$2.44B
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment ...[Read more]
Industry
Biotechnology
IPO Date
2016-08-11
Stock Exchange
NASDAQ
Ticker
PTGX
According to Protagonist Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.32B. This represents a change of 28.70% compared to the average of 1.81B of the last 4 quarters.
The mean historical Enterprise Value of Protagonist Therapeutics, Inc. over the last ten years is 432.05M. The current 2.32B Enterprise Value has changed 53.67% with respect to the historical average. Over the past ten years (40 quarters), PTGX's Enterprise Value was at its highest in in the September 2024 quarter at 2.66B. The Enterprise Value was at its lowest in in the June 2015 quarter at 0.
Average
432.05M
Median
214.29M
Minimum
59.53M
Maximum
1.47B
Discovering the peaks and valleys of Protagonist Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 249.45%
Maximum Annual Enterprise Value = 1.47B
Minimum Annual Increase = -73.94%
Minimum Annual Enterprise Value = 59.53M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.12B | 170.24% |
2022 | 412.96M | -71.84% |
2021 | 1.47B | 151.95% |
2020 | 582.03M | 249.45% |
2019 | 166.56M | 143.93% |
2018 | 68.28M | -73.94% |
2017 | 262.02M | 114.96% |
2016 | 121.89M | 88.11% |
2015 | 64.80M | 8.85% |
The current Enterprise Value of Protagonist Therapeutics, Inc. (PTGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
998.47M
5-year avg
748.80M
10-year avg
432.05M
Protagonist Therapeutics, Inc.’s Enterprise Value is less than Revolution Medicines, Inc. (8.35B), greater than Akero Therapeutics, Inc. (1.84B), less than Avidity Biosciences, Inc. (3.88B), greater than Stoke Therapeutics, Inc. (539.79M), greater than Kura Oncology, Inc. (760.34M), less than Merus N.V. (2.53B), greater than Replimune Group, Inc. (914.93M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Relay Therapeutics, Inc. (731.03M), greater than Pliant Therapeutics, Inc. (844.72M), greater than Black Diamond Therapeutics, Inc. (142.17M), greater than Arvinas, Inc. (1.47B), greater than Ventyx Biosciences, Inc. (133.83M), greater than IDEAYA Biosciences, Inc. (1.97B), less than Verona Pharma plc (3.06B), greater than Syndax Pharmaceuticals, Inc. (1.08B), greater than Terns Pharmaceuticals, Inc. (300.26M), greater than X4 Pharmaceuticals, Inc. (110.53M), greater than Acumen Pharmaceuticals, Inc. (127.78M), greater than Day One Biopharmaceuticals, Inc. (906.98M), greater than HOOKIPA Pharma Inc. (-35490856.00),
Company | Enterprise Value | Market cap |
---|---|---|
8.35B | $8.47B | |
1.84B | $2.12B | |
3.88B | $4.25B | |
539.79M | $687.51M | |
760.34M | $793.19M | |
2.53B | $2.96B | |
914.93M | $952.30M | |
8.24B | $8.19B | |
731.03M | $833.57M | |
844.72M | $864.12M | |
142.17M | $142.59M | |
1.47B | $1.55B | |
133.83M | $184.55M | |
1.97B | $2.35B | |
3.06B | $3.27B | |
1.08B | $1.21B | |
300.26M | $569.09M | |
110.53M | $129.73M | |
127.78M | $130.97M | |
906.98M | $1.33B | |
-35490856.00 | $21.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protagonist Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Protagonist Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Protagonist Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Protagonist Therapeutics, Inc. (PTGX)?
What is the 3-year average Enterprise Value for Protagonist Therapeutics, Inc. (PTGX)?
What is the 5-year average Enterprise Value for Protagonist Therapeutics, Inc. (PTGX)?
How does the current Enterprise Value for Protagonist Therapeutics, Inc. (PTGX) compare to its historical average?